Mind-body therapy

Phase 2Small molecule

NNational Human Genome Research Institute (NHGRI)

Mind-body therapy is one of 4 small molecule programs targeting Ehlers-Danlos syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ehlers-Danlos SyndromeActive, not recruiting

Ehlers-Danlos SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Ehlers-Danlos Syndrome

#DrugCompanyPhaseTrials

Enzastaurin

Eli Lilly

Phase 3

1 2

Pitocin

RRetrophin

Phase 2

1 3

Mind-body therapy

NNational Human Genome Research Institute (NHGRI)

Phase 2

1 4

Riboflavin

CCornea and Laser Eye Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT00001966·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mind-body therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mind-body therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mind-body therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Human Genome Research Institute (NHGRI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Human Genome Research Institute (NHGRI)

Mind-body therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

References

Drug Info

Quick Facts

Related News